Evidence · Systematic review or meta-analysis
Vaginal progesterone decreases preterm birth ≤ 34 weeks of gestation in women with a singleton pregnancy and a short cervix: an updated meta-analysis including data from the OPPTIMUM study.
- Medical
- Neurodevelopmental follow-up
- Neurology
This paper is from 2016, more than five years ago. Newer evidence may have been published since.
Summary
Updated systematic review and meta-analysis of five randomised trials (974 women), including OPPTIMUM data, comparing vaginal progesterone with placebo in asymptomatic women with a singleton pregnancy and a mid-trimester short cervix. Vaginal progesterone reduced preterm birth at or before 34 weeks or fetal death, as well as neonatal morbidity and mortality. No deleterious effects on neurodevelopmental outcome were found. The authors support universal transvaginal cervical length screening at 18-24 weeks.
Summary written for NICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to NICUlearn members, and Neeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.